

[Pegaspargase](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01XX24](#)

EMLc

Indication

Lymphoid leukaemia, not elsewhere classified ICD11 code: [2B33.3](#)

INN

Pegaspargase

Medicine type

Biological agent

List type

Core

Additional notes

Including quality-assured biosimilars

Formulations

Parenteral > General injections > IV: 3750 units per 5 mL in vial ; 3750 units in vial powder for injection

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Biological Cancer

Wikipedia

[Pegaspargase](#)

[DrugBank](#)

[Pegaspargase](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of pegaspargase powder for injection 3750 units in vial to the EML and EMLc.